Search  in | Advanced
   Print  

Transfusion-Related Acute Lung Injury (TRALI)

Transfusion-related acute lung injury (TRALI) is a serious complication of blood transfusions that is thought to be most commonly caused by a reaction to White Blood Cell antibodies present primarily in the plasma component of blood products. When transfused, these antibodies can sometimes activate a type of White Blood Cell called a granulocyte, which causes plasma to leak into the lungs, creating fluid accumulation — a condition referred to as acute pulmonary edema. According to the Food and Drug Administration, TRALI is a leading cause of transfusion-related deaths in both male and female patients, contributing to an average of 24 fatalities annually from 2003-2005. 

Plasma containing blood components obtained from certain donors are thought to carry a higher risk of causing TRALI. Donors who are more likely to have these antibodies include women who have been pregnant and developed these antibodies as a result of exposure to fetal blood and donors who have previously received a transfusion or transplant.

There is currently no screening test for the prevention of TRALI, and there is no single intervention that can eliminate the risk of TRALI.

Quick Links:
Misconceptions about TRALI Risk Reduction Recommendations 
Association Bulletin #06-07 (Members Only)


03/07

Back

Last modified on 4/2/2007 10:51:43 AM
What's New!
Significant Changes to the Standards for Cellular Therapy Product Services, 3rd edition
Details
Proposed 6th edition of Standards for Immunohematology Reference Laboratories
Details
AABB Weekly Report - July 18, 2008
Details
First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
Details
Billing and Reimbursement for Stem Cell Processing - Frequently Asked Questions and Answers
Details
Member Feedback Sought for AABB Online Forums
Details
Joint Statement Before ACBSA on the Clinical Significance of Red Cell Age in Transfusions
Details
Announcement of Nominees for the AABB Board of Directors
Details
2008 West Nile Virus Biovigilance Network
Details
Association Bulletin #08-03 - West Nile Virus – Revised Recommendations for Triggering Individual Donation Nucleic Acid Testing and Use of Communication Plans
Details
List of AABB-Accredited Facilities with Approved Variances for ISBT 128
Details
Instructions on Applying for an AABB Variance
Details